Lupin Limited (NSE:LUPIN)
1,984.60
+24.10 (1.23%)
Jul 29, 2025, 3:30 PM IST
Lupin Revenue
In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B INR with 13.48% growth. Lupin had revenue of 56.67B in the quarter ending March 31, 2025, with 14.24% growth.
Revenue
227.08B
Revenue Growth
+13.48%
P/S Ratio
3.99
Revenue / Employee
9.46M
Employees
24,006
Market Cap
906.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 274.80B |
Mankind Pharma | 122.07B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Fortis Healthcare | 77.86B |
Lupin News
- 12 days ago - Lupin’s Pithampur Unit-3 gets 3 observations from US FDA after inspection - Business Upturn
- 13 days ago - Lupin launches generic Lotemax ophthalmic suspension in the U.S. market - Business Upturn
- 25 days ago - Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market - Business Upturn
- 4 weeks ago - Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel; Eligible for 180-day generic exclusivity - Business Upturn
- 4 weeks ago - Lupin carves out LupinLife into separate consumer healthcare subsidiary to focus on OTC consumer wellness market - Business Upturn
- 6 weeks ago - Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal - Business Upturn
- 7 weeks ago - Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets - Business Upturn
- 2 months ago - Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025 - Business Upturn